INCY — INCYTE CORP catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

9 verified catalyst event(s) for INCYTE CORP (ticker INCY). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-08-10 — A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-08-10 in 4d ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa Phase 3 · NonSegmental Vitiligo	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-09-01 in 26d ESTIMATED	READOUT Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-interm Phase 3 · Diffuse Large B-cell Lymphoma	INCY INCYTE CORP	Tafasitamab, Lenalidomide, Rituximab, Cy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-09-28 in 2mo ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Phase 2 · Cutaneous Squamous Cell Carcinoma	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-09 in 2mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-09 in 2mo ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-19 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-10-19 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-05 in 3mo ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-11-20 in 4mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 2 · Moderate to Severe Asthma	INCY INCYTE CORP	povorcitinib, ICS-LABA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change